In breast cancer, simultaneous inhibition of the estrogen receptor and CDK4/6 leads to greater reduction in RB phosphorylation than monotherapy and has led to significant gains in survival (VanArsdale et al., 2015; Cristofanilli et al., 2016; Turner et al., 2018). This evidence concerns the gene ESR1 and breast carcinoma.